TY - JOUR T1 - Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00411-2021 VL - 7 IS - 4 SP - 00411-2021 AU - Andreas Jung AU - Annalisa Orenti AU - Fiona Dunlevy AU - Elina Aleksejeva AU - Egil Bakkeheim AU - Vladimir Bobrovnichy AU - Siobhán B. Carr AU - Carla Colombo AU - Harriet Corvol AU - Rebecca Cosgriff AU - Géraldine Daneau AU - Deniz Dogru AU - Pavel Drevinek AU - Andrea Dugac Vukic AU - Isabelle Fajac AU - Alice Fox AU - Stojka Fustik AU - Vincent Gulmans AU - Satenik Harutyunyan AU - Elpis Hatziagorou AU - Irena Kasmi AU - Hana Kayserová AU - Elena Kondratyeva AU - Uroš Krivec AU - Halyna Makukh AU - Kestutis Malakauskas AU - Edward F. McKone AU - Meir Mei-Zahav AU - Isabelle de Monestrol AU - Hanne Vebert Olesen AU - Rita Padoan AU - Tsitsino Parulava AU - Maria Dolores Pastor-Vivero AU - Luísa Pereira AU - Guergana Petrova AU - Andreas Pfleger AU - Liviu Pop AU - Jacqui G. van Rens AU - Milan Rodic´ AU - Marc Schlesser AU - Valérie Storms AU - Oxana Turcu AU - Lukasz Woz´niacki AU - Panayiotis Yiallouros AU - Anna Zolin AU - Damian G. Downey AU - Lutz Naehrlich Y1 - 2021/10/01 UR - http://openres.ersjournals.com/content/7/4/00411-2021.abstract N2 - Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes.Methods In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis.Results Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0–18.4). Median age was 24 years, 48.4% were male and 9.4% had lung transplants. SARS-CoV-2 incidence was higher in lung-transplanted (28.6; 95% CI: 22.7–35.5) versus non-lung-transplanted pwCF (16.6; 95% CI: 15.4–17.8) (p≤0.001).SARS-CoV-2 infection caused symptomatic illness in 75.7%. Factors associated with symptomatic SARS-CoV-2 infection were age >40 years, at least one F508del mutation and pancreatic insufficiency.Overall, 23.7% of pwCF were admitted to hospital, 2.5% of those to intensive care, and regretfully 11 (1.4%) died. Hospitalisation, oxygen therapy, intensive care, respiratory support and death were 2- to 6-fold more frequent in lung-transplanted versus non-lung-transplanted pwCF.Factors associated with hospitalisation and oxygen therapy were lung transplantation, cystic fibrosis-related diabetes (CFRD), moderate or severe lung disease and azithromycin use (often considered a surrogate marker for Pseudomonas aeruginosa infection and poorer lung function).Conclusion SARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s <70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes.In a European study of #SARSCoV2 infection in 828 people with #cysticfibrosis, those with moderate–severe lung disease, CF-related diabetes and lung transplant had poorer outcomes. People with CF, especially these groups, should shield in priority. https://bit.ly/3vPjD2f ER -